These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9734613)

  • 1. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
    Smith AC; Toto R; Bakris GL
    Kidney Int; 1998 Sep; 54(3):889-96. PubMed ID: 9734613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium-channel blockers for treatment of diabetic nephropathy.
    Murray KM
    Clin Pharm; 1991 Nov; 10(11):862-5. PubMed ID: 1794222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
    O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
    J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease.
    Kloke HJ; Wetzels JF; Koene RA; Huysmans FT
    Nephrol Dial Transplant; 1998 Mar; 13(3):646-50. PubMed ID: 9550641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcium channel blocking agents and albuminuria in diabetic and hypertensive patients. A pilot study].
    Lamarre-Cliche M; Lambert R; Van Nguyen P; Cusson J; Wistaff R; Larochelle P
    Arch Mal Coeur Vaiss; 2000 Aug; 93(8):919-24. PubMed ID: 10989730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
    Ruggenenti P; Mosconi L; Sangalli F; Casiraghi F; Gambara V; Remuzzi G; Remuzzi A
    Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converting enzyme inhibition and glomerular size selectivity in diabetic nephropathy.
    Meyer TW; Morelli E; Loon N; Peters W; Myers BD
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S64-8. PubMed ID: 16989068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
    Bakris GL; Copley JB; Vicknair N; Sadler R; Leurgans S
    Kidney Int; 1996 Nov; 50(5):1641-50. PubMed ID: 8914031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class differences in the effects of calcium channel blockers in the rat remnant kidney model.
    Griffin KA; Picken MM; Bakris GL; Bidani AK
    Kidney Int; 1999 May; 55(5):1849-60. PubMed ID: 10231447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy of lacidipine in patients with chronic glomerulonephritis and diabetic nephropathy].
    Lapchyns'ka II; Zhurylo TIe; Seliuk MM; Hromova AIe
    Lik Sprava; 2002; (2):116-20. PubMed ID: 12073241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
    Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load.
    Garini G; Mazzi A; Buzio C; Mutti A; Allegri L; Savazzi G; Borghetti A
    Nephrol Dial Transplant; 1996 Apr; 11(4):628-34. PubMed ID: 8671850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
    Bakris GL; Mangrum A; Copley JB; Vicknair N; Sadler R
    Hypertension; 1997 Mar; 29(3):744-50. PubMed ID: 9052890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glomerular permselectivity in early stages of overt diabetic nephropathy.
    Andersen S; Blouch K; Bialek J; Deckert M; Parving HH; Myers BD
    Kidney Int; 2000 Nov; 58(5):2129-37. PubMed ID: 11044234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
    Daina E; Cravedi P; Alpa M; Roccatello D; Gamba S; Perna A; Gaspari F; Remuzzi G; Ruggenenti P
    Nephron; 2015; 130(1):13-20. PubMed ID: 25895746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
    Bakris GL; Weir MR; Secic M; Campbell B; Weis-McNulty A
    Kidney Int; 2004 Jun; 65(6):1991-2002. PubMed ID: 15149313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charge selectivity of proteinuria in diabetic glomerulopathy.
    Nakamura Y; Myers BD
    Diabetes; 1988 Sep; 37(9):1202-11. PubMed ID: 3410164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of proteinuria in diabetic nephropathy. II. A study of the size-selective glomerular filtration barrier.
    Friedman S; Jones HW; Golbetz HV; Lee JA; Little HL; Myers BD
    Diabetes; 1983 May; 32 Suppl 2():40-6. PubMed ID: 6086024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.